
Associate Professor
Medicine
+1 415 353-2497
Dr. Lianne Gensler is a rheumatologist and serves as director of the UCSF Ankylosing Spondylitis Clinic, which is dedicated to care for this inflammatory disease.
Gensler's primary research interest is the disease progression of axial spondyloarthritis (a category that includes ankylosing spondylitis). Her research also seeks to identify predictors of osteoporosis development in patients with systemic lupus erythematosus.
Gensler earned her medical degree at the University of California, Irvine. She completed an internal medicine residency, chief residency and rheumatology fellowship at UCSF, and subsequently joined the medical staff in the rheumatology program.
Interests: Clinical outcomes, osteoporosis and radiographic progression
Publications
Trends in Opioid Prescriptions in Individuals with Axial Spondyloarthritis in the US and UK in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data.
Arthritis care & research
Entheseal bone remodeling and patient reported outcomes in osteoarthritis - A quantitative [18F]NaF-PET MRI study.
Osteoarthritis and Cartilage
ASAS recommendations on reporting axial spondyloarthritis clinical trials.
Annals of the Rheumatic Diseases
Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations.
Pharmacoepidemiology and Drug Safety
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2B/3 Trials.
The Journal of rheumatology
Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.
Rheumatology (Oxford, England)
Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies.
Rheumatology (Oxford, England)
POS0118 ASAS RECOMMENDATIONS ON REPORTING OUTCOMES OF CORE OUTCOME SET INSTRUMENTS IN AXIAL SPONDYLOARTHRITIS CLINICAL TRIALS.
Annals of the Rheumatic Diseases
POS0773 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: LONG-TERM RESULTS FROM PHASE 2B/3 TRIALS.
Annals of the Rheumatic Diseases
POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION.
Annals of the Rheumatic Diseases
POS0864 ACHIEVEMENT OF REMISSION DEFINED BY ABSENCE OF OBJECTIVE SIGNS OF INFLAMMATION VERSUS ASDAS INACTIVE DISEASE IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES.
Annals of the Rheumatic Diseases
POS0920 BIMEKIZUMAB DEMONSTRATES COMPARABLE ONE-YEAR EFFICACY IN MALE AND FEMALE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES.
Annals of the Rheumatic Diseases
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.
Rheumatology (Oxford, England)
Sex-related differences in efficacy and safety outcomes in axial spondyloarthritis randomized clinical trials: A systematic literature review and meta-analysis.
Arthritis care & research
The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.
Annals of the Rheumatic Diseases
1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis.
Annals of the Rheumatic Diseases
Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis) Commencing Late in Life.
The Journal of rheumatology
Le traitement par bimekizumab a été efficace à 2ans, quelle que soit la durée des symptômes de l’axSpA : résultats de deux essais de phase III.
Revue du Rhumatisme
Prologue: Spondyloarthritis Unmet Research Needs Conference IV.
The Journal of rheumatology
Unmet Needs in Spondyloarthritis: Imaging in Axial Spondyloarthritis.
The Journal of rheumatology
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.
Annals of the Rheumatic Diseases
Comment on: Effect of gender and age on bDMARD efficacy for axial spondyloarthritis patients: a meta-analysis of randomized controlled trials.
Rheumatology (Oxford, England)
Low socioeconomic status and female sex are associated with worse functional status in axial spondyloarthritis.
Arthritis care & research
ASAS consensus definition of early axial spondyloarthritis.
Annals of the Rheumatic Diseases
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase 2/3 Clinical Trials.
The Journal of rheumatology
The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis.
Seminars in arthritis and rheumatism
AB0881 LONG-TERM SAFETY AND TOLERABILITY OF BIMEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM POOLED PHASE 2B/3 STUDIES.
Annals of the Rheumatic Diseases
AB0913 EFFICACY OF CERTOLIZUMAB PEGOL IN PREVENTING ANTERIOR UVEITIS FLARES COMPARED WITH STANDARD NON-BIOLOGIC TREATMENT: A MATCHED CONTROL STUDY IN HIGH-RISK PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
Annals of the Rheumatic Diseases
POS0194 FACTORS ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING IL-17A INHIBITOR OR TNF INHIBITOR THERAPY: A POST-HOC ANALYSIS OF THE SURPASS STUDY.
Annals of the Rheumatic Diseases
POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION.
Annals of the Rheumatic Diseases
POS0391 THE MSQUASH AS MEASUREMENT TOOL FOR DAILY PHYSICAL ACTIVITY: TRANSLATION AND CROSS-CULTURAL ADAPTATION INTO ENGLISH, FIELD-TESTING IN DIFFERENT RHEUMATIC DISEASES AND CLINICAL VALIDATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
Annals of the Rheumatic Diseases
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES.
Annals of the Rheumatic Diseases
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford, England)
Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: Results from a head-to-head randomized phase IIIb study.
Arthritis & rheumatology (Hoboken, N.J.)
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Rheumatology and therapy
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
Annals of the Rheumatic Diseases
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Annals of the Rheumatic Diseases
Faibles taux d’uvéites chez les patients atteints de spondyloarthrite axiale traités par bimékizumab : résultats regroupés des essais de phase IIb/III.
Revue du Rhumatisme
Structural disease modification in axial spondyloarthritis.
Best practice & research. Clinical rheumatology
Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort.
Seminars in arthritis and rheumatism
Incidence rate and factors associated with fractures among Medicare beneficiaries with ankylosing spondylitis in the United States.
Arthritis care & research
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis.
ACR open rheumatology
44092 Tuberculid reactions at a US academic medical center: A retrospective review.
Journal of the American Academy of Dermatology
44261 Cutaneous tuberculosis at a US academic medical center: A retrospective review.
Journal of the American Academy of Dermatology
Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis.
Therapeutic advances in musculoskeletal disease
Tuberculid reactions: A multi-institution cohort study from 2 academic medical centers in the United States.
JAAD International
Cutaneous tuberculosis: A multi-institution cohort study from 2 academic medical centers in the United States.
JAAD International
Effect of Biologics in Subgroups of Axial Spondyloarthritis Based on Magnetic Resonance Imaging and C-Reactive Protein: A Systematic Review and Meta-Analysis.
ACR open rheumatology
The Association of Psoriasis with Rheumatic Diseases: A National Cross-Sectional Study.
Journal of the American Academy of Dermatology
POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS.
Annals of the Rheumatic Diseases
AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C-REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS.
Annals of the Rheumatic Diseases
AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES.
Annals of the Rheumatic Diseases
OP0055 ASAS CONSENSUS DEFINITION OF EARLY AXIAL SPONDYLOARTHRITIS.
Annals of the Rheumatic Diseases
OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY.
Annals of the Rheumatic Diseases
POS0665 INCIDENCE RATE AND FACTORS ASSOCIATED WITH FRACTURES AMONG ADULTS WITH ANKYLOSING SPONDYLITIS IN THE UNITED STATES.
Annals of the Rheumatic Diseases
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS.
Annals of the Rheumatic Diseases
POS0683 AN EXPLORATORY ANALYSIS OF THE POTENTIAL DISCONNECT BETWEEN OBJECTIVE INFLAMMATORY RESPONSE AND CLINICAL RESPONSE FOLLOWING CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS.
Annals of the Rheumatic Diseases
POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES.
Annals of the Rheumatic Diseases
POS1115 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SUBGROUP ANALYSES BY BASELINE SYNDESMOPHYTES AND C-REACTIVE PROTEIN STATUS.
Annals of the Rheumatic Diseases
Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis.
Arthritis research & therapy
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.
Annals of the Rheumatic Diseases
Sleep disturbance improves with SARS-COV2 vaccinations in patients with Chronic Inflammatory Disease.
Arthritis care & research
Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials.
The Journal of rheumatology
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
Annals of the Rheumatic Diseases
A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination.
Journal of clinical virology plus
Virtually Speaking: The Impact of a Nationwide Synchronous and Asynchronous Learning Forum.
Arthritis care & research
The faecal microbiota is distinct in HLA-B27+ ankylosing spondylitis patients versus HLA-B27+ healthy controls.
Clinical and experimental rheumatology
Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study.
Arthritis & rheumatology (Hoboken, N.J.)
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
Rheumatology (Oxford, England)
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
Annals of the Rheumatic Diseases
Why Do Some Patients Have Severe Sacroiliac Disease But No Syndesmophytes in Ankylosing Spondylitis? Data From a Nested Case-Control Study.
The Journal of rheumatology
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis.
Nature reviews. Rheumatology
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.
Annals of the Rheumatic Diseases
Reactogenicity of the mRNA SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease.
Arthritis care & research
Correction: Stoll et al. Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients. Children 2022, 9, 569.
Children (Basel, Switzerland)
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
ACR open rheumatology
Instrument selection for the ASAS core outcome set for axial spondyloarthritis.
Annals of the Rheumatic Diseases
OP0017 RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY.
Annals of the Rheumatic Diseases
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY.
Annals of the Rheumatic Diseases
OP0023 A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG.
Annals of the Rheumatic Diseases
OP0154 COMORBIDITY CLUSTERS IN ANKYLOSING SPONDYLITIS AND THEIR ASSOCIATION WITH DISEASE ACTIVITY AND FUNCTIONAL IMPAIRMENT: DATA FROM THE PSOAS COHORT.
Annals of the Rheumatic Diseases
POS0299 EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION AND INFLAMMATION IN SACROILIAC JOINTS AND SPINE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR IMAGING OUTCOMES FROM A PHASE III RANDOMISED TRIAL.
Annals of the Rheumatic Diseases
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY.
Annals of the Rheumatic Diseases
POS0941 LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS.
Annals of the Rheumatic Diseases
COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis.
Rheumatology and therapy
Single Cell Transcriptome and Surface Epitope Analysis of Ankylosing Spondylitis Facilitates Disease Classification by Machine Learning.
Frontiers in immunology
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis: A 15-year follow up study of the PSOAS Cohort.
Rheumatology (Oxford, England)
The relationship between body mass index, disease activity, and exercise in ankylosing spondylitis.
Arthritis care & research
Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients.
Children (Basel, Switzerland)
Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning.
Frontiers in immunology
Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial.
Arthritis care & research
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
The lancet. Gastroenterology & hepatology
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Therapeutic advances in musculoskeletal disease
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
BMC musculoskeletal disorders
A single center evaluation of applicant experiences in virtual interviews across eight internal medicine subspecialty fellowship programs.
Medical education online
The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort.
The Journal of rheumatology
Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante : résultats à 3 ans d’une étude de phase IIb.
Revue du Rhumatisme
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT.
Arthritis research & therapy
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
Annals of internal medicine
The ASAS-OMERACT core domain set for axial spondyloarthritis.
Seminars in arthritis and rheumatism
Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis.
ACR open rheumatology
OP0255 THE ROLE OF PELVIC MORPHOLOGY IN AXIAL SPONDYLOARTHRITIS.
Annals of the Rheumatic Diseases
POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY.
Annals of the Rheumatic Diseases
POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY.
Annals of the Rheumatic Diseases
POS0904 FACTORS ASSOCIATED WITH SWITCHING FROM ONE ANTI-TNF AGENT TO ANOTHER ANTI-TNF, OR IL17 AGENT IN PATIENT WITH ANKYLOSING SPONDYLITIS.
Annals of the Rheumatic Diseases
POS0923 INFLUENCE OF BASELINE DEMOGRAPHICS ON IMPROVEMENTS IN DISEASE ACTIVITY MEASURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING UPADACITINIB: A POST HOC SUBGROUP ANALYSIS OF SELECT-AXIS 1.
Annals of the Rheumatic Diseases
POS1255 REACTOGENICITY OF SARS-COV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASE.
Annals of the Rheumatic Diseases
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Annals of the Rheumatic Diseases
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Annals of the Rheumatic Diseases
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis.
Annals of the Rheumatic Diseases
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2.
medRxiv : the preprint server for health sciences
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase 3 Studies.
The Journal of rheumatology
Do geography and ethnicity play a role in juvenile Spondyloarthritis? A multi-center binational retrospective study.
Pediatric rheumatology online journal
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.
Rheumatology and therapy
Efficacité et tolérance à 52 semaines de l’ixékizumab dans la spondyloarthrite axiale radiographique chez des patients en réponse inadéquate ou intolérants aux anti-TNF.
Revue du Rhumatisme
Ixékizumab dans la spondyloarthrite axiale non-radiographique : résultats d’un essai de phase 3.
Revue du Rhumatisme
Le genre, l’âge ou la sous-population influencent-ils le maintien de la rémission clinique dans la spondyloarthrite axiale après une réduction de la dose de certolizumab pegol?.
Revue du Rhumatisme
Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis.
Arthritis care & research
Patient-reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID-19 Pandemic.
ACR open rheumatology
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
The Journal of rheumatology
The changing profile of ankylosing spondylitis in the biologic era.
Clinical rheumatology
Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study.
The Journal of rheumatology
AB1358-HPR DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS: A PRIMARY UNMET EDUCATIONAL NEED FOR RHEUMATOLOGISTS.
Annals of the Rheumatic Diseases
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE.
Rheumatology and therapy
Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey.
ACR open rheumatology
Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci.
Investigative ophthalmology & visual science
OP0060 MACHINE LEARNING BASED BERLIN SCORING OF MAGNETIC RESONANCE IMAGES OF THE SPINE IN PATIENTS WITH ANKYLOSING SPONDYLITIS FROM THE MEASURE 1 STUDY.
Annals of the Rheumatic Diseases
OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?.
Annals of the Rheumatic Diseases
OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY.
Annals of the Rheumatic Diseases
OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY.
Annals of the Rheumatic Diseases
THU0384 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PATIENTS: RESULTS FROM THE COAST-X TRIAL AT 52 WEEKS.
Annals of the Rheumatic Diseases
THU0395 EFFICACY OF IXEKIZUMAB ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND OBJECTIVE SIGNS OF INFLAMMATION, STRATIFIED BY BASELINE CRP/SACROILIAC JOINT MRI STATUS.
Annals of the Rheumatic Diseases
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Annals of the Rheumatic Diseases
Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
Clinical rheumatology
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
Annals of the Rheumatic Diseases
Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort.
Rheumatology international
Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review.
Therapeutic advances in musculoskeletal disease
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
Clinical drug investigation
A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis.
Clinical rheumatology
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Lancet (London, England)
A Terminal Event. Reply.
The New England journal of medicine
A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values.
Journal of biopharmaceutical statistics
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Annals of the Rheumatic Diseases
Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap.
Rheumatology and therapy
Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype?
Clinical and experimental rheumatology
A Terminal Event.
The New England journal of medicine
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Arthritis & rheumatology (Hoboken, N.J.)
Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.
Annals of the Rheumatic Diseases
MR distribution of active inflammatory and chronic structural sacroiliac joint changes in axial spondyloarthropathy: Challenging conventional wisdom.
Clinical imaging
AB0711 IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS AND SPINAL INFLAMMATION OF ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THROUGH ONE YEAR OF TREATMENT IN BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUG-NAÏVE PATIENTS.
Abstracts accepted for Publication
AB1321 PSYCHOMETRIC PROPERTIES OF THE ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE AS/RADIOGRAPHIC AXIAL SPA WHO HAVE PRIOR INADEQUATE RESPONSE/INTOLERANCE TO TNF INHIBITORS IN A PHASE 3 TRIAL.
Abstracts accepted for Publication
FRI0380 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES.
Spondyloarthritis – treatment
FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE.
Spondyloarthritis – treatment
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W.
Spondyloarthritis – treatment
FRI0408 EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES.
Spondyloarthritis – treatment
THU0385 COMPARISON OF CLINICAL AND DEMOGRAPHIC FEATURES OF JUVENILE SPONDYLOARTHRITIS BETWEEN ISRAELI AND US CHILDREN.
Poster Presentations
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.
Arthritis & rheumatology (Hoboken, N.J.)
Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis.
Best practice & research. Clinical rheumatology
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
Arthritis & rheumatology (Hoboken, N.J.)
Nonradiographic axial spondyloarthritis.
Best practice & research. Clinical rheumatology
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Lancet (London, England)
HLA class I and II alleles in susceptibility to ankylosing spondylitis.
Annals of the Rheumatic Diseases
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study.
Annals of the Rheumatic Diseases
Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.
Annals of the Rheumatic Diseases
OP0198 Combined effects of tumour necrosis factor inhibitors and nsaids on radiographic progression in ankylosing spondylitis.
Annals of the Rheumatic Diseases
THU0242 Pregnancy outcomes and disease activity in women with axial spondyloarthritis: a systematic literature review.
Annals of the Rheumatic Diseases
A multiple imputation method based on weighted quantile regression models for longitudinal censored biomarker data with missing values at early visits.
BMC medical research methodology
Successful treatment of mucous membrane pemphigoid with bortezomib.
JAAD case reports
Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort.
The Journal of rheumatology
Clinical Images: Ochronotic arthropathy.
Arthritis & rheumatology (Hoboken, N.J.)
Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups.
Clinical rheumatology
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
Annals of the Rheumatic Diseases
FRI0474 Does axial spondyloarthritis phenotype correlate with imaging morphotype?.
Annals of the Rheumatic Diseases
SAT0465 An integrated safety data analysis across all phase ii and phase iii clinical programs for ustekinumab in psoriatic arthritis, crohn's disease, and psoriasis.
Annals of the Rheumatic Diseases
Validity and Responsiveness of a 10-Item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population.
Arthritis care & research
Cervical Spinal Fracture and Other Diagnoses Associated With Mortality in Hospitalized Ankylosing Spondylitis Patients.
Arthritis care & research
FRI0398 Pharmacologic Therapy and Radiographic Progression in Ankylosing Spondylitis: A Growing Controversy.
Annals of the Rheumatic Diseases
FRI0434 Prevalence of Structural Cardiac Disease and Diastolic Dysfunction in Axial Spondyloarthritis: A Prospective Case-Control Study.
Annals of the Rheumatic Diseases
SAT0380 Nsaids Modify The Effect of Tumor Necrosis Factor Inhibitors on New Bone Formation in Ankylosing Spondylitis.
Annals of the Rheumatic Diseases
SAT0400 Clinical Factors Impacting Statin Usage in A Longitudinal Ankylosing Spondylitis Cohort.
Annals of the Rheumatic Diseases
Physical activity in axial spondyloarthritis-tails from bench to bedside.
Clinical rheumatology
ECHOCARDIOGRAPHIC EVALUATION OF CARDIOVASCULAR DISEASE IN ANKYLOSING SPONDYLITIS: A PROSPECTIVE CASE-CONTROL STUDY.
Journal of the American College of Cardiology
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Arthritis care & research
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Arthritis & rheumatology (Hoboken, N.J.)
Updates in adult-onset Still disease: Atypical cutaneous manifestations and associations with delayed malignancy.
Journal of the American Academy of Dermatology
Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.
Nature communications
Axial spondyloarthritis: the heart of the matter.
Clinical rheumatology
ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients.
Annals of the Rheumatic Diseases
Reply: To PMID 25154344.
Arthritis & rheumatology (Hoboken, N.J.)
Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis.
Arthritis & rheumatology (Hoboken, N.J.)
Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
Best practice & research. Clinical rheumatology
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns.
Arthritis & rheumatology (Hoboken, N.J.)
New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey.
Arthritis & rheumatology (Hoboken, N.J.)
Spine fractures in ankylosing spondylitis: a case report and review of imaging as well as predisposing factors to falls and fractures.
Seminars in arthritis and rheumatism
Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis.
Annals of the Rheumatic Diseases
Development and validation of the spondyloarthritis radiography module for calibration of readers using the modified Stoke Ankylosing Spondylitis Spine Score.
Arthritis care & research
The impact of tumor necrosis factor a inhibitors on radiographic progression in ankylosing spondylitis.
Arthritis and rheumatism
FRI0468 Socioeconomic status predicts radiographic progression in ankylosing spondylitis.
Annals of the Rheumatic Diseases
MICA, a gene contributing strong susceptibility to ankylosing spondylitis.
Annals of the Rheumatic Diseases
SAT0273 Lower socioeconomic status and smoking are associated with greater radiographic disease severity in axial spondyloarthritis.
Annals of the Rheumatic Diseases
Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative?
Arthritis care & research
Glucocorticoids: complications to anticipate and prevent.
The Neurohospitalist
Neutrophilic urticaria with systemic inflammation: a case series.
JAMA dermatology
Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.
Arthritis care & research
Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease.
Arthritis care & research
Is there a higher genetic load of susceptibility loci in familial ankylosing spondylitis?
Arthritis care & research
The "knowns" and "unknowns" of biologic therapy in ankylosing spondylitis.
The American journal of the medical sciences
Association of Sweet's Syndrome and Systemic Lupus Erythematosus.
Case reports in rheumatology
112 Clinical features of ankylosing spondylitis.
Rheumatology
Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort.
Annals of the Rheumatic Diseases
Recognition and treatment of juvenile-onset spondyloarthritis.
Current opinion in rheumatology
Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Clinical problem-solving. One surprise after another.
The New England journal of medicine
Longitudinal study of vascular remodeling in coronary arteries after heart transplantation.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Does use of intravascular ultrasound accelerate arteriopathy in heart transplant recipients?
American heart journal
Custom Person Type